New Japanese encephalitis vaccines: Alternatives to production in mouse brain

Expert Review of Vaccines

Volumn 10, Issue 3, 2011, Pages 355-364

  Halstead, Scott B ^a   Thomas, Stephen J ^b  

^a Research Program   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

clinical features; epidemiology; flavivirus; Japanese encephalitis; vaccines

Indexed keywords

ALPHA INTERFERON; BIKEN; HEPATITIS A VACCINE; IMOJEV; JAPANESE ENCEPHALITIS VACCINE; PLACEBO; RIBAVIRIN; SA 14142; STEROID; UNCLASSIFIED DRUG;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNIZATION; JAPANESE ENCEPHALITIS; MYALGIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MICE; VACCINES, ATTENUATED; VACCINES, COMBINED; VACCINES, INACTIVATED; YELLOW FEVER VACCINE;

EID: 79953245621     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.7     Document Type: Review

References (100)

1. Halstead S, Jacobson J. Japanese encephalitis vaccines In:Vaccines. Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, PA, USA, 311-352 (2008). The reference book on vaccines.
2. Erlanger TE, Weiss S, Keiser J, Utzinger J, Wiedenmayer K. Past, present, and future of Japanese encephalitis. Emerg. Infect. Dis. 15(1), 1-7 (2009).
3. Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 59(RR-1), 1-27 (2010). Updated source of Japanese encephalitis (JE) vaccine recommendations.
4. Solomon T. Flavivirus encephalitis. N. Engl. J. Med. 351(4), 370-378 (2004). Excellent clinical review.
5. Wittesjo B, Eitrem R, Niklasson B, Vene S, Mangiafico JA. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345(8953), 856-857 (1995).
6. Caramello P, Canta F, Balbiano R et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J. Travel Med. 14(5), 346-348 (2007).
7. Halstead SB, Grosz CR. Subclinical Japanese encephalitis. I. Infection of Americans with limited residence in Korea. Am. J. Hyg. 75, 190-201 (1962).
8. Benenson MW, Top FH Jr, Gresso W, Ames CW, Altstatt LB. The virulence to man of Japanese encephalitis virus in Thailand. Am. J. Trop. Med. Hyg. 24(6 Pt 1), 974-980 (1975).
9. Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bull. World Health Organ. 73(2), 237-244 (1995).
10. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 42(RR-1), 1-15 (1993).
11. Centers for Disease Control and Prevention (CDC). Japanese encephalitis among three U.S. travelers returning from Asia, 2003-2008. MMWR Morb. Mortal. Wkly Rep. 58(27), 737-740 (2009).
12. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am. J. Trop. Med. Hyg. 82(5), 930-936 (2010).
13. Macdonald WB, Tink AR, Ouvrier RA et al. Japanese encephalitis after a two-week holiday in Bali. Med. J. Aust. 150(6), 334-336, 339 (1989).
14. Centers for Disease Control and Prevention (CDC). Japanese encephalitis in a U.S. traveler returning from Thailand, 2004. MMWR Morb. Mortal. Wkly Rep. 54(5), 123-125 (2005).
15. Rose MR, Hughes SM, Gatus BJ. A case of Japanese B encephalitis imported into the United Kingdom. J. Infect. 6(3), 261-265 (1983).
16. Burdon JT, Stanley PJ, Lloyd G, Jones NC. A case of Japanese encephalitis. J. Infect. 28(2), 175-179 (1994).
17. Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand. J. Infect. Dis. 28(2), 189 (1996).
18. Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J. Travel Med. 16(3), 217-219 (2009).
19. Saito M, Sunagawa T, Makino Y et al. Three Japanese encephalitis cases in Okinawa, Japan, 1991. Southeast Asian J. Trop. Med. Public Health 30(2), 277-279 (1999).
20. Monnet FP. Behavioural disturbances following Japanese B encephalitis. Eur. Psychiatry 18(6), 269-273 (2003).
21. Geraghty CM, McCarthy JS. Japanese encephalitis vaccine: is it being sufficiently used in travellers? Med. J. Aust. 181(5), 269-270 (2004).
22. Hanson JP, Taylor CT, Richards AR, Smith IL, Boutlis CS. Japanese encephalitis acquired near Port Moresby: implications for residents and travellers to Papua New Guinea. Med. J. Aust. 181(5), 282-283 (2004).
23. Ostlund MR, Kan B, Karlsson M, Vene S. Japanese encephalitis in a Swedish tourist after travelling to Java and Bali. Scand. J. Infect. Dis. 36(6-7), 512-513 (2004).
24. Cutfield NJ, Anderson NE, Brickell K, Hueston L, Pikholz C, Roxburgh RH. Japanese encephalitis acquired during travel in China. Intern. Med. J. 35(8), 497-498 (2005).
25. Lehtinen VA, Huhtamo E, Siikamaki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J. Clin. Virol. 43(1), 93-95 (2008).
26. Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis. 161(5), 878-882 (1990).
27. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol. 267, 171-194 (2002).
28. Vaughn D, Barrett A, Solomon T. Flaviviruses (yellow fever, dengue, dengue hemorrhagic fever, Japanese encephalitis, West Nile, St. Louis encephalitis, tick-borne encephalitis). In:Principals and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds). Elsevier, Philadelphia, PA, USA, 2133-2156 (2009). The reference book on clinical infectious diseases.
29. Solomon T, Dung NM, Kneen R et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 125(Pt 5), 1084-1093 (2002).
30. Dickerson RB, Newton JR, Hansen JE. Diagnosis and immediate prognosis of Japanese B encephalitis; observations based on more than 200 patients with detailed analysis of 65 serologically confirmed cases. Am. J. Med. 12(3), 277-288 (1952).
31. Kimura K, Dosaka A, Hashimoto Y, Yasunaga T, Uchino M, Ando M. Single-photon emission CT findings in acute Japanese encephalitis. AJNR Am. J. Neuroradiol. 18(3), 465-469 (1997).
32. Misra UK, Kalita J, Jain SK, Mathur A. Radiological and neurophysiological changes in Japanese encephalitis. J. Neurol. Neurosurg. Psychiatr. 57(12), 1484-1487 (1994).
33. Kumar R, Mathur A, Singh KB et al. Clinical sequelae of Japanese encephalitis in children. Indian J. Med. Res. 97, 9-13 (1993).
34. Solomon T, Dung NM, Wills B et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 361(9360), 821-826 (2003).
35. Harinasuta C, Nimmanitya S, Titsyakorn U. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J. Trop. Med. Public Health 16(2), 332-336 (1985).
36. Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin. Infect. Dis. 48(4), 400-406 (2009).
37. Hammon WM, Tigertt WD, Sather GE, Berge TO, Meiklejohn G. Epidemiologic studies of concurrent virgin epidemics of Japanese B encephalitis and of mumps on Guam, 1947-1948, with subsequent observations including dengue, through 1957. Am. J. Trop. Med. Hyg. 7(4), 441-467 (1958).
38. Libraty DH, Nisalak A, Endy TP, Suntayakorn S, Vaughn DW, Innis BL. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans. R. Soc. Trop. Med. Hyg. 96(2), 173-178 (2002).
39. Luo D, Yao R, Song J, Huo H, Wang Z. The effect of DDT spraying and bed nets impregnated with pyrethroid insecticide on the incidence of Japanese encephalitis virus infection. Trans. R. Soc. Trop. Med. Hyg. 88(6), 629-631 (1994).
40. Luo D, Zhang K, Song J et al. The protective effect of bed nets impregnated with pyrethroid insecticide and vaccination against Japanese encephalitis. Trans. R. Soc. Trop. Med. Hyg. 88(6), 632-634 (1994).
41. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18(Suppl. 2), 26-32 (2000).
42. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23(45), 5205-5211 (2005). Valuable resource discussing immune readouts for JE vaccine development and clinical testing.
43. Paulke-Korinek M, Kollaritsch H. Japanese encephalitis and vaccines: past and future prospects. Wien. Klin. Wochenschr. 120(19-20 Suppl. 4), 15-19 (2008).
44. Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst. Rev. (3), CD004263 (2007). Expansive review of the JE vaccine literature.
45. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines 7(5), 689-693 (2008).
46. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol. Rec. 80(28), 242-247 (2005).
47. Hoke CH, Nisalak A, Sangawhipa N et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319(10), 608-614 (1988)
48. Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin. Biol. Ther. 8(1), 95-106 (2008).
49. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 337(8748), 1044 (1991).
50. Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 338(8771), 881-882 (1991).
51. Ishikawa T, Konishi E. Combating Japanese encephalitis: Vero-cell derived inactivated vaccines and the situation in Japan. Future Virol. 5(6), 785-799 (2010).
52. Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19(31), 4557-4565 (2001).
53. Bista MB, Banerjee MK, Shin SH et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358(9284), 791-795 (2001).
54. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366(9494), 1375-1378 (2005).
55. Tandan JB, Ohrr H, Sohn YM et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 25(27), 5041-5045 (2007).
56. Kumar R, Tripathi P, Rizvi A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N. Engl. J. Med. 360(14), 1465-1466 (2009).
57. Gatchalian S, Yao Y, Zhou B et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 26(18), 2234-2241 (2008).
58. Solomon T. Control of Japanese encephalitis-within our grasp? N. Engl. J. Med. 355(9), 869-871 (2006).
59. Yu Y. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities. Vaccine 28(21), 3635-3641 (2010).
60. Abe M, Shiosaki K, Hammar L et al. Immunological equivalence between mouse brain-derived and Vero cell-derived Japanese encephalitis vaccines. Virus Res. 121(2), 152-160 (2006).
61. Kuzuhara S, Nakamura H, Hayashida K et al. Non-clinical and Phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine. Vaccine 21(31), 4519-4526 (2003).
62. Sugawara K, Nishiyama K, Ishikawa Y et al. Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30(4), 303-314 (2002).
63. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 9(7), 921-931 (2009). Valuable review of IC51 development history and pathway.
64. Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ. Japanese encephalitis virus live-attenuated vaccine Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 6(6), 513-518 (1988).
65. Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev. Biol. Stand. 70, 27-47 (1989).
66. Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25(17), 3445-3453 (2007).
67. Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet 370(9602), 1847-1853 (2007).
68. Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebo-controlled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis. 198(4), 493-499 (2008).
69. Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 26(34), 4382-4386 (2008).
70. Schuller E, Klade CS, Wolfl G, Kaltenbock A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15), 2188-2193 (2009).
71. Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine IXIARO (IC51), in 6 months of follow-up. Vaccine 28(39), 6463-6469 (2010).
72. Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151-6156 (2008).
73. Kaltenbock A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine Havrix1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 27(33), 4483-4489 (2009).
74. Dubischar-Kastner K, Eder S, Buerger V et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 28(32), 5197-5202 (2010).
75. Kaltenbock A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 28(3), 834-839 (2010).
76. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73(4), 3095-3101 (1999).
77. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28(3), 632-649 (2010). Excellent summary of the development of Yellow fever-based chimeric vaccines.
78. Monath TP, Soike K, Levenbook I et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17(15-16), 1869-1882 (1999).
79. Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am. J. Trop. Med. Hyg. 62(4), 480-484 (2000).
80. Monath TP, McCarthy K, Bedford P et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine 20(7-8), 1004-1018 (2002).
81. Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188(8), 1213-1230 (2003).
82. Torresi J, McCarthy K, Feroldi E, Meric C. Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled Phase 3 trials. Vaccine 28(50), 7993-8000 (2010).
83. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U et al. Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr. Infect. Dis. J. 29(12), 1111-1117 (2010).
84. Nasveld PE, Marjason J, Bennett S et al. Concomitant or sequential administration of live attenuated japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind Phase II evaluation of safety and immunogenicity. Hum. Vaccin. 6(11), 906-914 (2010).
85. Nasveld PE, Ebringer A, Elmes N et al. Long term immunogenicity of live attenuated Japanese encephalitis chimeric virus vaccine: randomized, double-blind, 5-year Phase II study in healthy adults. Hum. Vaccin. 6(10), 1038-1046 (2010).
86. WTO. Yearbook of tourism statistics: data 2000-2004. Nations U (Ed.). World Tourism Organization, Madrid, Spain (2006).
87. Hatz C, Werlein J, Mutsch M, Hufnagel M, Behrens RH. Japanese encephalitis: defining risk incidence for travelers to endemic countries and vaccine prescribing from the UK and Switzerland. J. Travel Med. 16(3), 200-203 (2009).
88. Ding D, Kilgore PE, Clemens JD, Wei L, Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai, China. Bull. World Health Organ. 81(5), 334-342 (2003).
89. Liu W, Clemens JD, Kari K, Xu ZY. Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine 26(35), 4456-4460 (2008).
90. Touch S, Suraratdecha C, Samnang C et al. A cost-effectiveness analysis of Japanese encephalitis vaccine in Cambodia. Vaccine 28(29), 4593-4599 (2010).
91. Siraprapasiri T, Sawaddiwudhipong W, Rojanasuphot S. Cost benefit analysis of Japanese encephalitis vaccination program in Thailand. Southeast Asian J. Trop. Med. Public Health 28(1), 143-148 (1997).
92. Japanese encephalitis virus vaccine inactivated www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123761.pdf (Accessed 27 September 2010)
93. Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies http://whqlibdoc.who.int/hq/2006/WHO-IVB-05. 19-eng.pdf (Accessed 21 September 2010)
94. PATH's Japanese Encephalitis Project www.path.org/projects/japanese- encephalitis-project.php (Accessed 21 September 2010)
95. Dynamic Synergy www.mt-pharma.co.jp/e/ir/annual/pdf/annual-2010-en.pdf (Accessed 22 November 2010)
96. Japanese Encephalitis vaccine www.intercell.com/main/forvaccperts/ products/japanese-encephalitis-vaccine (Accessed 27 September 2010)
97. MILVAX - Japanese encephalitis www.vaccines.mil/default.aspx?cnt=disease/ minidv&dID=31 (Accessed 21 September 2010)
98. Novel vaccine IMOJEV™ for the prevention of Japanese encephalitis in children and adults living in Asia www.avpi.org/sanofi-pasteur2/ImageServlet? imageCode=26033&siteCode=SP-CORP (Accessed 10 September 2010)
99. Clinical Trials.gov search Japanese Encephalitis http://clinicaltrials. gov/ct2/results?term=japanese+encephalitis (Accessed 10 September 2010)
100. UNWTO Tourism Highlights, Edition 2010 www.unwto.org/facts/eng/ highlights.htm (Accessed 10 October 2010)